Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04436965
Other study ID # 2019-FXY-348-NPC
Secondary ID
Status Recruiting
Phase Phase 3
First received
Last updated
Start date August 16, 2021
Est. completion date December 15, 2024

Study information

Verified date January 2023
Source Sun Yat-sen University
Contact Jingjing Miao, MD
Phone 86-13631355201
Email miaojingjing90@163.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a multicenter, randomized controlled, phase III clinical trial. The purpose of this study is to evaluate the efficacy of standard nutrition treatment versus conventional nutrition treatment in local advanced nasopharyngeal carcinoma patients.


Recruitment information / eligibility

Status Recruiting
Enrollment 266
Est. completion date December 15, 2024
Est. primary completion date July 15, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: - Newly histologic diagnosis of nasopharyngeal carcinoma(WHO II/III); - All genders,range from 18~65 years old; - Karnofsky performance status(KPS) = 80; - Clinical stage III~IVa(AJCC/UICC 8th); - Without significant digestive system disease,nutritional and metabolic diseases or endocrine disease - Without significant cardiac,respiratory,kidney or liver disease; - Not received radiotherapy, chemotherapy and other anti-tumor treatment(including immunotherapy); - White blood cell(WBC) count = 4×109/L, neutrophile granulocyte(NE) count = 1.5×109/L, Hemoglobin(HGB) = 9g/L, platelet(PLT) count = 100×109/L - Total bilirubin(TBIL)?alanine aminotransferase (ALT) or aspartate aminotransferase(AST) < 2.5×upper limit of normal(ULN); - Adequate renal function: BUN/CRE = 1.5×ULN or endogenous creatinine clearance = 60ml/min (Cockcroft-Gault formula); - No contraindications to chemotherapy or radiotherapy; - Inform consent form; Exclusion Criteria: - Have some PEG/PEJ contraindications, such as coagulopathy, recent anticoagulant medications and aspirin, gastric ulcer or history of gastric bleeding, portal hypertension combined with abdominal and esophageal fundal varices, pyloric obstruction due to residual stomach under the costal arch after various major gastrectomy or various reasons; - Distance metastases; - Have or are suffering from other malignant tumors; - Participating in other clinical trials; - Drug or alcohol addition; - Do not have full capacity for civil acts; - Mental disorder; - Pregnancy or lactation; - Severe complication, eg, uncontrolled hypertension;

Study Design


Intervention

Other:
Standardized nutrition therapy
Standardized nutrition therapy with ONS, nasal feeding tube, PEG or parenteral nutrition
Drug:
Cisplatin
Patients in both arms received concurrent cisplatin chemotherapy:100 mg/m² cisplatin given intravenously every 3 weeks on days 1, 22 concurrently with radiotherapy.
Radiation:
Intensity Modulated Radiation Therapy
Patients in both arms received Intensity Modulated Radiation Therapy:All target volumes were outlined slice by slice on the axial contrast-enhanced CT with MR fusion images in the treatment planning system. The target volumes were defined in accordance with the International Commission on Radiation Units and Measurements Reports 83. The prescribed dose was 70-72 Gy to PTVnx (Planning target volume of the primary tumor), 64-70 Gy to PTVnd (Planning target volume of the cervical lymph node),60- 64Gy to PTV1 (Planning target volume 1), and 54-58 Gy to PTV2 (Planning target volume 2) in 30-32 fractions. The details of dose limits for organs at risk were based on the study 0225 from The Radiation Therapy Oncology Group (RTOG 0225).

Locations

Country Name City State
China Sun Yat-sen University Cancer Center Guangzhou Guangdong

Sponsors (10)

Lead Sponsor Collaborator
Sun Yat-sen University Cancer Hospital of Guizhou Province, Fudan University, Fujian Cancer Hospital, Jiangxi Provincial Cancer Hospital, The First Affiliated Hospital of Xiamen University, Wuhan University, Xiangya Hospital of Central South University, Xijing Hospital, Zhejiang Cancer Hospital

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary The incidence of IBW% To observe the changes and differences in the incidence of the actual weight/ideal weight (IBW%) less than 90% during the treatment of the two groups of patients 2 months
Secondary The incidence of WL?UBW% and BMI To observe the changes and differences in the incidence of body weight loss (WL)=5%/10%, actual body weight/usual body weight (UBW%), body mass index (BMI) before, during and after treatment 36 months
Secondary Number of Participants With Abnormal Laboratory Values To observe patients' complete blood cell count and blood biochemical examination during the treatment and three years after the treatment. 36 months
Secondary Overall survival From date of recruited to death 36 months
Secondary Progression free survival From date of recruited to disease progression 36 months
Secondary Locoregional recurrence free survival From date of recruited to locoregional recurrence 36 months
Secondary Distant metastasis free survival From date of recruited to distant metastasis 36 months
Secondary Nutrition screening and evaluation To observe the changes and differences of nutrition screening and evaluation (NRS2002 and PG-SGA) before, during and after treatment in the two groups 36 months
Secondary Quality of life: EuroQoL 5 dimension Evaluating with questionnaire of EuroQoL 5 dimension, 5 level health state utility index (EQ-5D-5L) 36 months
Secondary Acute toxicities Evaluating with CTCAE v5.0 through study completion, an average of 2 months
Secondary Late toxicity assessed with Radiation Therapy Oncology Group radiation morbidity scoring criteria 36 months
See also
  Status Clinical Trial Phase
Recruiting NCT05979961 - Phase III Trial of Concurrent Chemotherapy Alone in Patients With Low-risk Nasopharyngeal Carcinoma Phase 3
Active, not recruiting NCT04242199 - Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors Phase 1
Recruiting NCT05415098 - Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas Phase 1
Recruiting NCT06055816 - Gemcitabine Combined With Endostar and Envafolimab in Elderly Patients With Locally Advanced Nasopharyngeal Carcinoma Phase 2
Recruiting NCT05547971 - Development of Intelligent Model for Radioactive Brain Damage of Nasopharyngeal Carcinoma Based on Radio-metabolomics
Not yet recruiting NCT05020925 - SHR-1701 in Combination With Famitinib in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma Phase 1/Phase 2
Not yet recruiting NCT04547088 - Camrelizumab Combined With Apatinib in Patients With First-line Platinum-resistant Recurrent/Metastatic Nasopharyngeal Carcinoma Phase 2
Not yet recruiting NCT04548271 - Camrelizumab Combined With Apatinib in Patients With PD-1 Antagonists Resistant Recurrent/Metastatic Nasopharyngeal Carcinoma Phase 2
Recruiting NCT02795169 - Trail Evaluating Carbon Ion Radiotherapy With Concurrent Chemotherapy for Locally Recurrent Nasopharyngeal Carcinoma Phase 1/Phase 2
Terminated NCT02801487 - Trial Evaluating Carbon Ion Radiotherapy With Concurrent Chemotherapy for Locally Recurrent Nasopharyngeal Carcinoma Phase 1/Phase 2
Terminated NCT02569788 - Trail Evaluating Carbon Ion Radiotherapy for Locally Recurrent Nasopharyngeal Carcinoma Phase 1/Phase 2
Completed NCT02237924 - Endostar Combined With Intensity-modulated Radiotherapy Compare With Chemoradiation for Nasopharyngeal Carcinoma Phase 2
Recruiting NCT02044562 - Dietary Nitrate on Plasma Nitrate Levels for Nasopharyngeal Carcinoma Patients N/A
Terminated NCT01694576 - NPC Staged N2-3M0:Adjuvant Chemotherapy or Just Observation After Concurrent Chemoradiation Phase 2
Recruiting NCT01462903 - A Study of Adoptive Immunotherapy With Autologous Tumor Infiltrating Lymphocytes in Solid Tumors Phase 1
Completed NCT01271439 - Study of Chemoradiotherapy Combined With Cetuximab in Nasopharyngeal Carcinoma Phase 2
Completed NCT00535795 - Phase III: Assess Conventional RT w/ Conventional Plus Accelerated Boost RT in the Treatment of Nasopharyngeal CA Phase 3
Completed NCT00379262 - Therapeutic Gain by Induction-concurrent Chemoradiotherapy and/or Accelerated Fractionation for Nasopharyngeal Carcinoma Phase 3
Completed NCT03398980 - Late Sequelae of Childhood and Adolescent Nasopharyngeal Carcinoma Survivors After Radiotherapy N/A
Completed NCT01309633 - Study Evaluating Two Loading Regimens of Sunitinib or Bevacizumab Alternating With Cisplatin and Gemcitabine as Induction Therapy for Locally Advanced Nasopharyngeal Carcinoma (NPC) Phase 2